Medications for Insomnia: A Guide to Prescription and Over-the-Counter Options

[1] American Academy of Sleep Medicine. (2017). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 13(2), 307-319.

[2] National Institute on Drug Abuse. (2021). Benzodiazepines. [https://www.drugabuse.gov/drug-topics/benzodiazepines](https://www.drugabuse.gov/drug-topics/benzodiazepines)

[3] Mayo Clinic. (2024). Insomnia - Diagnosis and treatment. [https://www.mayoclinic.org/diseases-conditions/insomnia/diagnosis-treatment/drc-20355173](https://www.mayoclinic.org/diseases-conditions/insomnia/diagnosis-treatment/drc-20355173)

[4] American Academy of Sleep Medicine. (2017). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 13(2), 307-319.

[5] National Institute of Mental Health. (n.d.). Mental Health Medications. [https://www.nimh.nih.gov/health/topics/mental-health-medications](https://www.nimh.nih.gov/health/topics/mental-health-medications)

[6] American Geriatrics Society. (2019). American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society, 67(4), 674-694.

[7] National Center for Complementary and Integrative Health. (2023). Melatonin: What You Need To Know. [https://www.nccih.nih.gov/health/melatonin-what-you-need-to-know](https://www.nccih.nih.gov/health/melatonin-what-you-need-to-know)

[8] National Center for Complementary and Integrative Health. (2023). Valerian. [https://www.nccih.nih.gov/health/valerian](https://www.nccih.nih.gov/health/valerian)

The Neuroscience of Sleep: Why Insomnia Is More Than "Not Being Tired"

Insomnia is not simply the absence of sleepiness — it is an active state of hyperarousal that prevents the brain from transitioning into sleep. Understanding the neuroscience of sleep and wakefulness explains why different medications work through different mechanisms and why some are more effective for certain insomnia subtypes.

The two-process model of sleep:

Sleep is regulated by two interacting processes:

1. Process S (sleep pressure): Adenosine accumulates in the brain during wakefulness, creating increasing "sleep pressure." Adenosine binds to A1 and A2A receptors, inhibiting wake-promoting neurons. Caffeine works by blocking adenosine receptors.
2. Process C (circadian rhythm): The suprachiasmatic nucleus (SCN) in the hypothalamus generates a ~24-hour rhythm that promotes wakefulness during the day and sleep at night, driven by light exposure and melatonin secretion.

The hyperarousal model of insomnia:

Chronic insomnia involves dysregulation of the arousal system — specifically, overactivation of the hypothalamic-pituitary-adrenal (HPA) axis and the noradrenergic system. People with insomnia have:

• Higher 24-hour cortisol levels
• Elevated body temperature at night
• Increased high-frequency EEG activity (beta waves) during sleep
• Higher metabolic rate during sleep

This explains why cognitive-behavioral therapy for insomnia (CBT-I) — which directly targets hyperarousal — is more effective than medications for long-term insomnia management.

Over-the-Counter Sleep Aids: What Works and What Doesn't

Diphenhydramine (Benadryl, ZzzQuil, Unisom SleepTabs):

The most widely used OTC sleep aid. An antihistamine that causes sedation by blocking H1 histamine receptors in the brain.

Efficacy: Modestly effective for short-term sleep onset difficulty. Reduces sleep onset latency by approximately 14 minutes and increases total sleep time by approximately 25 minutes in clinical trials.

Problems:

• Tolerance develops rapidly (within 3–4 days): Histamine receptors upregulate in response to chronic blockade, rendering the medication ineffective with regular use
• Anticholinergic effects: Dry mouth, constipation, urinary retention, blurred vision, cognitive impairment
• Residual sedation ("hangover"): Long half-life (8–12 hours) causes next-day drowsiness and impaired driving
• Dementia risk: Long-term anticholinergic use is associated with increased dementia risk in older adults. The BEERS criteria list diphenhydramine as potentially inappropriate for adults over 65.

Recommendation: Acceptable for occasional use (1–2 nights per week) in adults under 65. Not recommended for chronic insomnia or for adults over 65.

Doxylamine (Unisom SleepTabs):

Similar to diphenhydramine; slightly longer half-life. Same limitations apply.

Melatonin:

Melatonin is a hormone produced by the pineal gland that signals darkness and promotes sleep onset. Exogenous melatonin is most effective for:

• Circadian rhythm disorders: Jet lag, shift work, delayed sleep phase syndrome
• Sleep onset insomnia (difficulty falling asleep, not staying asleep)
• Older adults: Melatonin production declines with age; supplementation may be more effective in this population

Dosing: Effective doses are much lower than commonly sold. 0.5–1 mg taken 30–60 minutes before desired sleep onset is as effective as 5–10 mg doses and produces less next-day grogginess. The common 5–10 mg doses sold OTC are pharmacological (not physiological) doses.

Timing matters: For sleep onset insomnia, take 30–60 minutes before bedtime. For jet lag, take at the destination bedtime for 3–5 days.

Safety: Generally safe for short-term use. Long-term safety data are limited. Not recommended during pregnancy.

Valerian root:

An herbal supplement with modest evidence for sleep improvement. A 2006 meta-analysis found that valerian may improve sleep quality without producing side effects, but the evidence is inconsistent across studies. Onset of effect may take 2–4 weeks with regular use.

Magnesium:

Magnesium deficiency is associated with insomnia. Magnesium glycinate or magnesium threonate (200–400 mg at bedtime) may improve sleep quality, particularly in older adults and those with magnesium deficiency. Well-tolerated with minimal side effects.

Prescription Sleep Medications: A Comprehensive Overview

Benzodiazepines (temazepam, triazolam, estazolam):

Enhance GABA-A receptor function, producing sedation, anxiolysis, and muscle relaxation.

Efficacy: Effective for short-term insomnia. Reduce sleep onset latency and increase total sleep time.

Problems:

• Dependence and withdrawal: Physical dependence develops within 2–4 weeks of regular use. Withdrawal causes rebound insomnia, anxiety, and (with abrupt discontinuation) seizures.
• Tolerance: Efficacy diminishes with regular use
• Cognitive impairment: Impair memory consolidation and next-day cognitive function
• Falls and fractures: Significant risk in older adults
• Respiratory depression: Contraindicated in sleep apnea

Current role: Generally reserved for short-term use (< 2 weeks) when other options have failed. Avoid in older adults, those with substance use disorders, and those with sleep apnea.

Z-drugs (zolpidem/Ambien, zaleplon/Sonata, eszopiclone/Lunesta):

Also enhance GABA-A receptors but with greater selectivity for sleep-promoting circuits than benzodiazepines.

Zolpidem (Ambien): Most prescribed sleep medication in the US. Effective for sleep onset. Immediate-release for sleep onset; extended-release (Ambien CR) for sleep maintenance.

Problems:

• Complex sleep behaviors: Sleepwalking, sleep-eating, sleep-driving — sometimes without memory. FDA issued a black box warning in 2019.
• Dependence: Less than benzodiazepines, but still significant
• Next-day impairment: Particularly at higher doses and in women (who metabolize zolpidem more slowly). FDA recommends lower doses for women (5 mg vs. 10 mg).
• Tolerance: Develops with regular use

Zaleplon (Sonata): Very short half-life (1 hour). Can be taken in the middle of the night if ≥ 4 hours remain before waking. Minimal next-day sedation.

Eszopiclone (Lunesta): Longer half-life than zolpidem; more effective for sleep maintenance. FDA approved for long-term use (the only z-drug with this approval).

Doxepin (Silenor) — low-dose:

At low doses (3–6 mg), doxepin is a highly selective H1 antihistamine. Unlike higher doses used for depression, low-dose doxepin has minimal anticholinergic effects.

Efficacy: Particularly effective for sleep maintenance insomnia (waking in the middle of the night or early morning). FDA approved for this indication.

Advantages: No dependence, no tolerance, minimal next-day sedation, safe in older adults (at low doses).

Suvorexant (Belsomra) and lemborexant (Dayvigo) — orexin receptor antagonists:

A newer class that blocks orexin (hypocretin) receptors. Orexin promotes wakefulness; blocking it allows sleep to occur.

Mechanism: Rather than inducing sedation, orexin antagonists reduce wakefulness — a fundamentally different approach that more closely mimics natural sleep.

Efficacy: Effective for both sleep onset and sleep maintenance insomnia.

Advantages: Lower dependence potential than benzodiazepines or z-drugs. No rebound insomnia. FDA approved for long-term use.

Disadvantages: Next-day somnolence at higher doses. Rare complex sleep behaviors. Expensive.

Ramelteon (Rozerem) — melatonin receptor agonist:

Activates MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus.

Efficacy: Modest effect on sleep onset latency (reduces by ~10 minutes). Not effective for sleep maintenance.

Advantages: No dependence, no tolerance, no abuse potential. Safe in older adults. No next-day impairment.

Best for: Mild sleep onset insomnia, circadian rhythm disorders, older adults, patients with substance use disorders.

Cognitive-Behavioral Therapy for Insomnia (CBT-I): The Gold Standard

Multiple clinical guidelines (American College of Physicians, American Academy of Sleep Medicine) recommend CBT-I as the first-line treatment for chronic insomnia — ahead of medications.

CBT-I components:

• Sleep restriction therapy: Temporarily limit time in bed to match actual sleep time, building sleep pressure
• Stimulus control: Strengthen the association between bed and sleep (no screens, work, or worrying in bed)
• Sleep hygiene: Consistent sleep/wake times, avoiding caffeine and alcohol, optimizing sleep environment
• Cognitive restructuring: Challenging dysfunctional beliefs about sleep ("I must get 8 hours or I can't function")
• Relaxation techniques: Progressive muscle relaxation, diaphragmatic breathing

Efficacy: CBT-I achieves remission rates of 50–70% in chronic insomnia, compared to 30–40% for medications. Effects are durable — maintained at 12–24 month follow-up — unlike medications, whose effects diminish with tolerance.

Access: CBT-I is available through sleep psychologists, online programs (Sleepio, SHUTi), and apps (Somryst — FDA-cleared digital therapeutic).

Frequently Asked Questions

Q: Is it safe to take melatonin every night?

A: Short-term use (up to 3 months) appears safe. Long-term safety data are limited. Melatonin is not habit-forming and does not cause rebound insomnia. Using the lowest effective dose (0.5–1 mg) minimizes any potential risks.

Q: Can I take sleep medication if I have sleep apnea?

A: With caution. Benzodiazepines and z-drugs can worsen sleep apnea by relaxing upper airway muscles and suppressing arousal responses. Orexin antagonists (suvorexant, lemborexant) and low-dose doxepin are safer options. Treating sleep apnea with CPAP often resolves insomnia without medication.

Q: How do I stop taking sleep medication after long-term use?

A: Taper gradually — reduce dose by 25% every 1–2 weeks. Implement CBT-I strategies during the taper to manage rebound insomnia. Work with your physician; abrupt discontinuation of benzodiazepines can cause seizures.

Special Populations: Tailoring Insomnia Treatment

Older adults:

Insomnia affects 40–70% of adults over 65. However, many standard sleep medications are inappropriate in this population:

• Benzodiazepines and z-drugs increase fall and fracture risk 2–3 fold
• Diphenhydramine causes significant cognitive impairment and is listed on the BEERS criteria as potentially inappropriate
• Preferred options: low-dose doxepin (3 mg), melatonin, ramelteon, suvorexant (5 mg), CBT-I

Pregnant women:

Most sleep medications are not recommended during pregnancy due to insufficient safety data. Options:

• CBT-I is safe and effective
• Diphenhydramine is category B (used for morning sickness) but not ideal for chronic use
• Melatonin: insufficient data; generally avoided
• Doxylamine (Unisom) is commonly used for morning sickness and considered relatively safe in pregnancy

Patients with substance use disorders:

Benzodiazepines and z-drugs carry significant abuse potential. Preferred options: CBT-I, ramelteon, low-dose doxepin, melatonin, orexin antagonists (suvorexant, lemborexant — lower abuse potential than z-drugs).

Patients with depression:

Insomnia and depression are bidirectionally linked — each worsens the other. Sedating antidepressants (mirtazapine, trazodone, doxepin) treat both conditions simultaneously. Trazodone (50–100 mg at bedtime) is widely used off-label for insomnia, though evidence for efficacy is modest.

Frequently Asked Questions

Q: Is it safe to take melatonin every night?

A: Short-term use (up to 3 months) appears safe. Melatonin is not habit-forming and does not cause rebound insomnia. Using the lowest effective dose (0.5–1 mg) minimizes any potential risks.

Q: Can I take sleep medication if I have sleep apnea?

A: With caution. Benzodiazepines and z-drugs can worsen sleep apnea by relaxing upper airway muscles. Orexin antagonists and low-dose doxepin are safer options. Treating sleep apnea with CPAP often resolves insomnia without medication.

Q: How do I stop taking sleep medication after long-term use?

A: Taper gradually — reduce dose by 25% every 1–2 weeks. Implement CBT-I strategies during the taper to manage rebound insomnia. Work with your physician; abrupt discontinuation of benzodiazepines can cause seizures.

Q: What is the safest sleep medication for long-term use?

A: CBT-I is the safest long-term intervention. Among medications, low-dose doxepin (3–6 mg), ramelteon, and orexin antagonists (suvorexant, lemborexant) have the most favorable long-term safety profiles, with no dependence, tolerance, or rebound insomnia.

Monitoring Treatment Response

When starting sleep medication, track these metrics weekly:

• Sleep onset latency: How long it takes to fall asleep (target < 30 minutes)
• Wake after sleep onset (WASO): Total time awake during the night (target < 30 minutes)
• Total sleep time: Aim for 7–9 hours for most adults
• Daytime functioning: Energy, concentration, mood, and performance at work

A sleep diary (paper or app-based) is the most practical tool. If sleep does not improve within 2–4 weeks, reassess the diagnosis and treatment plan.

The Role of Sleep Hygiene

Medication works best when combined with good sleep hygiene:

• Consistent sleep schedule: Same bedtime and wake time every day, including weekends
• Dark, cool, quiet bedroom: Use blackout curtains, earplugs, or white noise as needed
• Avoid screens 1 hour before bed: Blue light suppresses melatonin
• Avoid caffeine after 2 PM: Caffeine has a half-life of 5–6 hours
• Avoid alcohol: Alcohol disrupts sleep architecture and causes rebound insomnia in the second half of the night
• Reserve the bed for sleep and sex only: Avoid working, watching TV, or using phones in bed